Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 513 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... May 18, 2021 The Horror Story Of What Can Happen When You Don’t Pay... September 16, 2019 Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age... March 23, 2020 Study Aims to Reduce Lung Cancer Stigma by Teaching Health Professionals... January 15, 2025 Load more HOT NEWS Body Location May Influence Fate of Cells with Cancer-Causing Mutations Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... EMA Recommends Granting a Marketing Authorisation for Equidacent Study Aims to Reduce Lung Cancer Stigma by Teaching Health Professionals...
